N@N

Derek Archila Maintained (BPMC) at Hold with Increased Target to $55 on, Jun 14th, 2023

Derek Archila of Wells Fargo, Maintained "Blueprint Medicines Corporation" (BPMC) at Hold with Increased Target from $48 to $55 on, Jun 14th, 2023.

Derek has made no other calls on BPMC in the last 4 months.

There are 10 other peers that have a rating on BPMC. Out of the 10 peers that are also analyzing BPMC, 3 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $46 on, Tuesday, May 23rd, 2023
• Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $55 on, Friday, May 5th, 2023
• Benjamin Chaiken of "JMP Securities" Reiterated at Hold and Held Target at $114 on, Tuesday, February 28th, 2023

These are the ratings of the 7 analyists that currently disagree with Derek

---

• Andrew Berens of "SVB Leerink" Downgraded from Hold to Sell and Decreased Target to $43 on, Monday, June 5th, 2023
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $85 on, Tuesday, May 23rd, 2023
• Liana Moussatos of "Wedbush" Reiterated at Buy and Held Target at $75 on, Tuesday, May 23rd, 2023
• Michael Schmidt of "Guggenheim" Maintained at Strong Buy with Increased Target to $82 on, Tuesday, May 23rd, 2023
• Reni Benjamin of "JMP Securities" Reiterated at Buy and Held Target at $114 on, Tuesday, May 23rd, 2023
• Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $67 on, Tuesday, May 23rd, 2023
• Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $85 on, Friday, February 17th, 2023

Contributing Sources

---